机构：[1]Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China[2]Department of Gastroenterology, The Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, China[3]Department of Urology, The First Affiliated Hospital of Guiyang College of Traditional Chinese Medicine, Guiyang, Guizhou Province, China[4]Guiyang College of Traditional Chinese Medicine, Guiyang, Guizhou Province, China[5]Liver Research Center, Brown University, Providence, USA
Objective: To investigate the cellular mechanisms of action of tanshinone IIA on the fatty liver
disease induced by a high-fat diet in an animal model of non-alcoholic fatty liver disease (NAFLD).
Methods: Adult male Sprague Dawley rats were randomized into one of three groups: regular
rat diet (CON group) for 4 months; high-fat diet (HFD group) for 4 months; HFD for 2 months
followed by tanshinone IIA treatment plus HFD (TAN group) for a further 2 months. A range of
physical and biochemical markers of lipid accumulation and fatty liver disease were measured and
compared between the groups.
Results: Tanshinone IIA treatment significantly reduced fat accumulation in the liver and plasma
lipid levels that had been increased by HFD. The toll-like receptor (TLR4)/nuclear factor kappa B
(NF-jB) signalling pathway was silenced by tanshinone IIA treatment. Tumour necrosis factor-a
and interleukin-6 were reduced by tanshinone IIA. Hepatocyte apoptosis was inhibited by tanshinone IIA. Tanshinone IIA upregulated peroxisome proliferator-activated receptor gamma
(PPAR-c), which resulted in an improvement in the oxidative status.
Conclusion: Tanshinone IIA ameliorates NAFLD by targeting PPAR-c and TLR4, resulting in
decreased plasma lipids and oxidative stress, suggesting this strategy may form the basis of novel
NAFLD therapies.
基金：
the Research Fund of Guangdong Gastrointestinal
Disease Research Centre (no. 2017B02029003),
the Human Health and Family Planning
Commission Research Fund (no. A2017014) and
the Special Scientific Research Fund of the Public
Welfare Profession of the National Health and
Family Planning Commission (no. 201502026).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
第一作者：
第一作者机构：[1]Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China[2]Department of Gastroenterology, The Second Affiliated Hospital of University of South China, Hengyang, Hunan Province, China
通讯作者：
通讯机构：[1]Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China[5]Liver Research Center, Brown University, Providence, USA[*1]Liver Research Center, Brown University, Providence, USA, Providence, RI 02912, USA.
推荐引用方式(GB/T 7714)：
Huang Lu,Ding Wei,Wang Ming-Qiang,et al.Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4.[J].The Journal of international medical research.2019,47(10):5239-5255.doi:10.1177/0300060519859750.
APA：
Huang Lu,Ding Wei,Wang Ming-Qiang,Wang Zheng-Gen,Chen Hong-Hui...&He Ji-Man.(2019).Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4..The Journal of international medical research,47,(10)
MLA：
Huang Lu,et al."Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4.".The Journal of international medical research 47..10(2019):5239-5255
